ImmuCell (ICCC) Q4 2024 earnings summary

Executive summary

• Achieved 52% sales growth in Q4 and full year 2024, with Q4 sales reaching $7.8M and full-year sales $26.5M, rebounding from prior production limitations due to contamination events.

• No contamination events since April 2024, reflecting effective remediation and improved quality control.

• Expanded production capacity for First Defense® to $30M+ annual sales value, with further expansion options.

• Key priorities include growing First Defense® sales, achieving FDA approval for Re-Tain®, and proving Re-Tain® market acceptance.

• Net income for Q4 2024 was $515K ($0.06/share) versus a net loss of $1.14M ($0.15/share) in Q4 2023; full-year net loss narrowed to $2.16M ($0.26/share) from $5.78M ($0.75/share) in 2023.

Financial highlights

• Gross margin improved to 37% in Q4 2024 (up from 25% in Q4 2023) and 30% for full-year 2024 (up from 22% in 2023).

• Q4 2024 EBITDA reached $1.33M, up from negative $311K in Q4 2023; full-year EBITDA $1.11M vs. negative $2.6M prior year.

• Cash and equivalents increased to $3.8M at year-end 2024 from $979K a year earlier.

• Net working capital rose to $10.6M from $7.3M; stockholders' equity up to $27.5M from $25M.

• Net loss narrowed to $2.2M in 2024 from $5.8M in 2023.

Outlook and guidance

• Awaiting FDA approval for Re-Tain®, with a controlled launch pending regulatory clearance; fourth CMC Technical Section submitted in January 2025.

• Operational improvements and increased production capacity position the company for continued growth in 2025.

• Plans to further expand First Defense® production capacity and pursue international regulatory approvals.

• Exploring strategic options to offset product development expenses and support a mass market launch for Re-Tain®.

• Focus remains on maintaining high production yields and avoiding future contamination or equipment breakdowns.